Patent Cliffs and Capital Drive Surge in Life Sciences M&A
With a reported $305 billion in revenue at risk from patent expirations, pharma companies are driving a 141% increase in M&A deal value, frequently using contingent value rights to bridge valuation gaps.
Life sciences M&A activity surged in the first half of 2026, with deal value reaching $196 billion—a 141% increase over the same period last year and the strongest start since 2019. This dealmaking frenzy is driven by an impending patent cliff, which places an estimated $305 billion in revenue at risk for pharmaceutical companies over the next seven years. To address the shortfall, acquirers are deploying significant capital to purchase de-risked assets, primarily those in Phase II clinical trials or later. Hot areas for acquisition include cardiometabolic and obesity treatments, late-stage oncology, and immunology. A notable structuring trend is the increased use of Contingent Value Rights (CVRs), which now feature in about one-third of public target deals to bridge valuation gaps by tying payments to future milestones. Given their potential for disputes, practitioners should carefully negotiate CVR terms, particularly the "efforts" standards that govern a buyer's obligations post-closing. Analysts expect the high volume of "bolt-on" acquisitions to continue, with a potential "mega-merger" on the horizon.